TABLE 1.
Recurrence | Cht (number of patients) |
---|---|
First | Bevacizumab + Irinotecan 12 (63.2%) |
BCNU 2 | |
TMZ 4 | |
PCV 1 | |
Second | Bevacizumab + Irinotecan 5 (26.3%) |
BCNU 1 | |
PCV 1 | |
Third | Bevacizumab + Irinotecan 2 (10.5%) |
BCNU = Carmustine (BCNU), 80 mg/m2 BCNU on days 1 on 3; Cht = chemotherapy; PCV = lomustine (CCNU), 110 mg/m2, on day 1; procarbazine, 60 mg/m2 on days 8 to 21; and vincristine, 1.5 mg/m2 (maximum dose, 2 mg), on days 8 and 29; TMZ = temozolomide, 150–200 mg/m2/day on days 1 to 5 of each subsequent 28-day cycle